The bivalent low affinity anti-LYPD1 TCB with 5 nM CD3-targeting arm QWG430 induced dose-dependent tumor regressions at 10 and 3 mg/kg (Fig. 5C and Supplementary Fig. 6F), while the bivalent low affinity anti-LYPD1 TCB with 16 nM CD3-targeting arm QZC131 was less active but still demonstrated dose-dependent tumor growth inhibition at 10 and 3 mg/kg (Fig. 5C and Supplementary Fig. 6G). Here, LYPD1 is linked to neoplasm.